Associated tags: Patient, Cancer, Disease, Hope, Pharmaceutical industry, Sale, Form 10-K, Form 10-Q, History, Research, Vaccine
Locations: BOSTON, SINGAPORE, MASSACHUSETTS, CA, BELTSVILLE, MD, US, CHICAGO
Insurance,
Cancer,
International Association,
Yale Cancer Center,
Lung cancer,
Research,
Lung,
Public expenditure,
AML,
Patient,
B7-H4,
Mab,
Conference,
Pharmaceutical industry,
Medical imaging,
Clothing,
Cryptocurrency,
Pembrolizumab,
Immunotherapy BELTSVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported second quarter 2023 financial results.
Key Points:
- BELTSVILLE, Md., Aug. 03, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported second quarter 2023 financial results.
- Financial Results for Quarter Ended June 30, 2023
Cash, cash equivalents, and marketable securities as of June 30, 2023, were $130.6 million as compared to $159.9 million as of December 31, 2022.
- Research and development expenses were $13.4 million for the quarter ended June 30, 2023, as compared to $12.8 million for the quarter ended June 30, 2022.
- General and administrative expenses were $5.7 million for the quarter ended June 30, 2023, as compared to $5.3 million for the quarter ended June 30, 2022.
CMML,
Myelodysplastic syndrome,
Survival,
Chronic myelomonocytic leukemia,
Cancer,
Acute myeloid leukemia,
AML,
Federation,
Patient,
Apoptosis,
Mab,
Federation of Clinical Immunology Societies,
Safety,
Vaccine “Our pre-clinical models showed that NC525 specifically eradicates leukemic stem cells (LSCs) and blast cells, while preserving healthy hematopoietic cells,” said Solomon Langermann, Ph.D., NextCure’s chief scientific officer.
Key Points:
- “Our pre-clinical models showed that NC525 specifically eradicates leukemic stem cells (LSCs) and blast cells, while preserving healthy hematopoietic cells,” said Solomon Langermann, Ph.D., NextCure’s chief scientific officer.
- “The data presented in the poster define the mechanism that leads to specific induction of apoptosis in leukemic cells, but not in healthy immune cells.
- High expression of LAIR-1 is seen on leukemic stem cells and blast cells, where it plays a role in survival of these cancer cells.
- The current Phase 1 study is an open-label, non-randomized, dose escalation trial to determine safety and tolerability of NC525 in adult patients with relapsed or refractory AML.
BELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the JMP Securities Life Sciences Conference in New York City on Tuesday, May 16th, at 11:30 am ET.
Key Points:
- BELTSVILLE, Md., May 09, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the JMP Securities Life Sciences Conference in New York City on Tuesday, May 16th, at 11:30 am ET.
- A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com .
- A replay of the webcast will be available after the event and archived on the website for 30 days.
Cancer,
Research,
Public expenditure,
AML,
Patient,
B7-H4,
Nursing,
Pharmaceutical industry,
Medical imaging,
Mineral wool,
Cryptocurrency Clinical data readouts expected in 2023 for NC410, NC762 and NC525 programs
Key Points:
- Clinical data readouts expected in 2023 for NC410, NC762 and NC525 programs
BELTSVILLE, Md., May 04, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases today provided a business update and reported first quarter 2023 financial results.
- Phase 1b update is expected in the fourth quarter of 2023.
- Research and development expenses were $11.6 million for the quarter ended March 31, 2023, as compared to $15.0 million for the quarter ended March 31, 2022.
- General and administrative expenses were $5.4 million for the quarter ended March 31, 2023, as compared to $5.7 million for the quarter ended March 31, 2022.
BELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th, at 10:15 am ET.
Key Points:
- BELTSVILLE, Md., April 11, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the 22nd Annual Needham Virtual Healthcare Conference on Wednesday, April 19th, at 10:15 am ET.
- A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com .
- A replay of the webcast will be available after the event and archived on the website for 30 days.
AML,
Research,
Cancer,
Patient,
Public expenditure,
Extracellular matrix,
B7-H4,
Pharmaceutical industry,
Medical imaging,
Mineral wool,
Cryptocurrency BELTSVILLE, Md., March 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided a business update and reported full year 2022 financial results.
Key Points:
- BELTSVILLE, Md., March 02, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today provided a business update and reported full year 2022 financial results.
- Continued enrollment in the Phase 1b dose expansion study in patients with solid tumors and high expression of B7-H4.
- Financial Results for Full Year Ended December 31, 2022
Cash, cash equivalents, and marketable securities as of December 31, 2022, were $159.9 million as compared to $219.6 million as of December 31, 2021.
- The change in net loss from the previous year was primarily due to higher research and development expenses.
Retrieved on:
Tuesday, February 7, 2023
BELTSVILLE, Md., Feb. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15th at 1:40 pm ET.
Key Points:
- BELTSVILLE, Md., Feb. 07, 2023 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the SVB Securities Global Biopharma Conference on Wednesday, February 15th at 1:40 pm ET.
- A live audio webcast will be available through the Investors section of the company’s website at www.nextcure.com .
- A replay of the webcast will be available after the event and archived on the website for 30 days.
Retrieved on:
Tuesday, November 22, 2022
Marketing,
History,
Conference,
Virtual,
Bank,
Patient,
Hematology,
JMP,
Form 10-Q,
Security (finance),
Sale,
Cancer,
Hope,
Form 10-K,
Pharmaceutical industry A replay of the webcasts will be available after the event and archived on the website for 30 days.
Key Points:
- A replay of the webcasts will be available after the event and archived on the website for 30 days.
- NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases.
- Forward-looking statements involve substantial risks and uncertainties that could cause actual results to differ materially from those projected in any forward-looking statement.
- NextCure assumes no obligation to update any forward-looking statements, even if expectations change.
Retrieved on:
Tuesday, November 15, 2022
Marketing,
ADC,
Control,
History,
Patient,
Form 10-Q,
Disease,
LCB,
Neoplasm,
Sale,
Cancer,
Form 10-K,
B7-H4,
Antibody-drug conjugate,
Therapy,
Research,
Hope,
KOSDAQ,
Fine chemical,
Pharmaceutical industry and DAEJEON, South Korea, Nov. 15, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets.
Key Points:
- and DAEJEON, South Korea, Nov. 15, 2022 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC) and LegoChem Biosciences, Inc. (LCB, KOSDAQ: 141080) today announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two additional targets.
- Under the terms of the agreement, both parties will equally share the costs to develop the molecules and profits on commercialized products.
- The parties will utilize their respective product development capabilities to generate the B7-H4 ADC and advance it to the clinic.
- Youshould not place undue reliance on any forward-looking statements.NextCureassumes no obligation to update any forward-looking statements, even if expectations change.
Associate,
Roswell Park Comprehensive Cancer Center,
Cytokine,
Research,
Tumor microenvironment,
Growth,
Sale,
GLOBE,
Form 10-K,
B7-H4,
Mouse,
Breast,
History,
Safety,
B cell,
NK,
Biopsy,
MSS,
NCI-designated Cancer Center,
Form 10-Q,
Patient,
Chemokine,
Nasdaq,
Marketing,
Immunotherapy,
Gynecologic Oncology (journal),
Ovary,
Head,
Hope,
Oncology,
Forward-looking statement,
Johns Hopkins School of Medicine,
Pembrolizumab,
Cancer,
Society,
SITC,
Department,
Society for Immunotherapy of Cancer,
Myelocyte,
Pharmaceutical industry,
Vaccine The initial clinical data come from a Phase 1 study evaluating NC762, a monoclonal antibody that binds specifically to B7-H4, in patients with advanced/metastatic solid tumors.
Key Points:
- The initial clinical data come from a Phase 1 study evaluating NC762, a monoclonal antibody that binds specifically to B7-H4, in patients with advanced/metastatic solid tumors.
- In addition, we are excited to enroll the safety component of the NC410 combo trial and to report initial data in mid-2023.
- Highlights include:
Data come from five patient cohorts (n=18), who received NC762 up to 20 mg/kg once every two weeks.
- The NC410 Phase 1b/2 combination trial is a multi-center, first-in-human, open-label, multi-arm trial to evaluate the efficacy of NC410 in combination with pembrolizumab.
